The Lancet Haematology in conversation with
Lan-Lan Smith, Editor-in-Chief, Cheryl Lai, Acting Deputy Editor, and Emma Cookson, Senior Editor at The Lancet Haematology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.
A monthly audio companion to the journal, this podcast covers a broad range of topics, from racial and ethnic disparities in leukaemia survival outcomes to resuscitation with blood products compared with saline, the link between mental health and lymphoma to haemolytic disease in newborns, and more.
- Update frequency
- every 44 days
- Average duration
- 15 minutes
- Episodes
- 59
- Years Active
- 2014 - 2025
A panel of the authors on our Lancet Haematology-Lancet Regional Health Western Pacific Series on mature T-cell and natural killer-cell lymphomas
Today, on World Lymphoma Awareness Day, Professors Yok Lam Kwong, Wee Joo Chng, and Eric Tse join us in this joint episode of The Lancet Haematology and The Lancet Regional Health - Western Pacific t…
Lan-Lan Smith, Cheryl Lai, and Daniela Marín discuss the EHA, ICML, and ISTH conferences
June has been packed with interesting haematology conferences so the editorial team behind The Lancet Haematology have gathered to share their thoughts and reflect on their experiences at the Europea…
Paolo Strati on off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma
Associate Professor Paolo Strati (Department of Lymphoma and Myeloma, and Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA) joins us to…
A panel of the authors on our Adverse Events Series on adverse event reporting in haematological malignancies
With a growing number of treatment options for blood cancers, understanding the side effects from these treatments and how they affect patients is becoming ever more important. Join a panel of author…
Michael Northend on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma
Dr Michael Northend (University College London Hospitals NHS Foundation Trust, and Cancer Research UK & UCL Cancer Trials Centre, London, UK) joins us to discuss the long-term results of a randomised…
Joanne Verweij and Romy Pothof on fetal and neonatal alloimmune thrombocytopenia
Dr Romy Pothof and Prof Joanne Verweij join us to discuss their development of an international consensus on the diagnosis and treatment of fetal and neonatal alloimmune thrombocytopenia.
Read the ful…
Helene Schoemans, Elke Stienissen, and Kathy Goris on a consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe
Prof Helene Schoemans, Elke Stienissen, and Kathy Goris join us to discuss the importance of consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe.
Continue thi…
Dawn Swan on air pollution and venous thromboembolism
Dr Dawn Swan joins us to discuss current knowledge and future perspectives on the possible association between air pollution and venous thromboembolism.
Read the full article:
https://www.thelancet.com…
Leslie Skeith on low-dose aspirin for postpartum venous thromboembolism prophylaxis
Dr Leslie Skeith joins us to discuss the PARTUM pilot trial, comparing low-dose aspirin versus placebo in postpartum venous thromboembolism.
Read the full article:
https://www.thelancet.com/journals/la…
Neema Mayor and Caitlin Farrow on impact of patient ethnicity on haematopoeietic cell transplantation outcome in the United Kingdom
Dr Neema Mayor and Dr Caitlin Farrow from the Anthony Nolan Research Institute join us to discuss the findings of their study on the impact of patient ethnicity on haematopoietic cell transplantation…
Lancet Haematology 10 year anniversary - meet the editors
In a special 10 year anniversary podcast, Lan-Lan Smith, Yaiza del Pozo Martin, and Emma Cookson, the editorial team behind The Lancet Haematology, reflect on the last decade and give some insights i…
Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome
Professor Matteo Giovanni Della Porta joins us to discuss the primary analysis of the phase 3 COMMANDS trial comparing luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, tran…
Kim Linton on follicular lymphoma
Dr Kim Linton joins us to discuss the EPCORE NHL-1 trial testing monotherapy with the bispecific antibody epcoritamab for patients with relapsed or refractory follicular lymphoma.
Read the full articl…
Judy Truong on ferritin reference levels and iron deficiency
Dr Judy Truong join us to discuss ferritin reference intervals and how adoption of evidence-based ferritin clinical decision limits can help clinicians detect and treat iron deficiency, minimising pr…
Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML
Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients wi…
Banu Aygun on sickle cell anaemia
Professor Banu Aygun joins us to discuss the REACH trial testing hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa.
Read the full article:
https://www.thelancet.…
Sabine Braat and Katherine Fielding on haemoglobin thresholds to define anaemia
Dr Sabine Braat and Dr Katherine Fielding join us to discuss their study presenting new haemoglobin thresholds for defining anaemia.
Read the full article:
https://www.thelancet.com/journals/lanhae/art…
Elisabeth Schorb on the MARTA phase 2 trial
Doctor Elisabeth Schorb joins us to discuss the MARTA phase 2 trial, treating older, fit patients with primary diffuse large B-cell CNS lymphoma with high-dose chemotherapy and autologous stem-cell t…
Stephan Ehl on paediatric autoimmune lymphoproliferative immunodeficiencies
Professor Stephan Ehl joins us to discuss a prospective observational study on paediatric autoimmune lymphoproliferative immunodeficiencies.
Read the full article:
https://www.thelancet.com/journals/la…
Dr Sarah O'Brien on the PREVAPIX-ALL trial
Dr Sarah O'Brien joins Lan-Lan Smith to discuss results of the phase 3 PREVAPIX-ALL trial, which compares direct oral anticoagulant apixaban to low-molecular-weight-heparin for the prevention of veno…